State of the ArtEvolving Strategies for Thrombolytic Therapy of Peripheral Vascular Occlusion
Section snippets
PHARMACOLOGY OF FIBRINOLYTIC AGENTS
The principal fibrinolytic agents currently in use or under investigation are outlined in Table 1 (1, 2, 3). Three of these drugs have been used extensively in the treatment of peripheral vascular occlusions; several others have been studied in a limited fashion. The goal of current thrombolytic drug design is to alter fibrin specificity, plasma half-life, and antigenicity to make safer and more effective agents.
Streptokinase (SK) (Streptase; AstraZeneca, Westborough, MA), the first widely used
THE ABBOKINASE STORY
Abbokinase has been produced by tissue culture techniques since 1978 (15). The drug is derived from kidney cells of Colombian premature neonates who have died of natural causes. After informed consent is obtained from the parents, kidney cells are harvested and processed by a tissue culture company in Colombia. Exhaustive screening for infectious agents follows. This process includes testing donor serum and one of the frozen ampules of extracted kidney cells for aerobic and anaerobic bacteria,
RT-PA IN PERIPHERAL ARTERIAL OCCLUSION
Table 2 outlines the results of the major published series involving regional rt-PA infusion therapy for thrombotic or embolic peripheral arterial or bypass graft occlusions (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27). Several conclusions can be drawn from analysis of these studies:
- 1.
rt-PA is effective in recanalizing acute and subacute PAO in approximately 70%–90% of cases. The wide range in success rates is partially caused by varying definitions for initial technical or clinical
RT-PA VERSUS OTHER FIBRINOLYTIC AGENTS IN PERIPHERAL ARTERIAL OCCLUSION
Table 3 outlines the principal studies that have directly compared rt-PA with SK or UK in treating acute PAO (29, 30, 31, 32, 33). Several conclusions can be drawn from these data:
- 1.
rt-PA is at least as effective as UK and SK in opening acute or subacute native arterial or bypass graft occlusions.
- 2.
rt-PA-based lysis is faster than UK-based lysis at the doses tested.
- 3.
There is a tendency toward more bleeding with rt-PA, although these differences were not statistically significant in all series.
INITIAL BOLUS DELIVERY OF RT-PA
In current practice, many interventional radiologists treat acute PAO by initially saturating the thrombus with a large dose of fibrinolytic agent via pulse-spray, lacing, or bolus technique to accelerate lysis and rapidly restore some flow to the ischemic extremity. This approach has been proven to accelerate clot lysis, presumably by increasing the surface area for plasminogen activation and by mechanically fragmenting thrombus (36, 37). Lysis is then completed by slower delivery of the agent
HEMORRHAGIC EVENTS WITH RT-PA
The primary concern of interventional radiologists who use rt-PA for PAO is the possibility of severe bleeding complications, most notably intracranial hemorrhage. This fear is fueled by reports of unusually high complication rates (including intracranial hemorrhage) in some series of thrombolysis, by the experience of cardiologists in treating acute coronary thrombosis with rt-PA, and by anecdotal reports (43, 44). Although rt-PA is far more specific for fibrin-bound plasminogen than for free
RT-PA IN EXTREMITY VENOUS THROMBOSIS
Most trials of rt-PA thrombolysis for lower extremity deep venous thrombosis have involved systemic administration of the drug with or without comparison to another fibrinolytic agent (51, 52, 53, 54, 55). Several recent reports describe local rt-PA therapy for extremity venous thrombosis (56, 57, 58, 59, 60, 61, 62, 63). A recent trial comparing regional rt-PA infusion (20 mg over the course of 4 h daily for up to 7 days) with regional UK infusion (100,000 IU/h for up to 7 days) described
RT-PA IN CLOTTED HEMODIALYSIS GRAFTS
Few published reports have focused on the use of rt-PA in thrombosed hemodialysis grafts and dialysis catheters, and most involved the now largely abandoned method of local infusion (66, 67, 68). With use of the pulse-spray pharmacomechanical technique, our group treated 23 clotted dialysis grafts with rt-PA (0.5 mg/mL) with a mean dose of 7.1 ± 3.6 mg and an average lytic infusion time of 32 minutes (69). All grafts were successfully opened. A single major bleeding complication occurred in a
RETEPLASE IN PERIPHERAL VASCULAR OCCLUSIONS
Catheter-directed thrombolysis of peripheral arterial, axillosubclavian vein, and iliofemoral venous thrombosis has been performed with use of reteplase in doses ranging from 0.5 to 1.0 U/h given over 5–24 hours, sometimes with an initial bolus (eg, 2-5U) (Centocor, data on file, 1999). Reteplase has also been used to treat clotted hemodialysis grafts with use of pulse-spray and “lyse and wait” techniques. When heparin is administered, it is often at no more than half the normal dose. There
COST OF FIBRINOLYTIC AGENTS
The approximate hospital costs for single vials of Streptase (250,000 U), Abbokinase (250,000 IU), Activase (50 mg), and Retavase (20 U) are $150, $380, $1,100, and $2,150, respectively. Despite the relatively low cost of Streptase, most interventionalists in the United States do not consider it to be an effective and safe alternative to other thrombolytic agents for peripheral vascular occlusions. By available unit dose, Abbokinase (if available) is considerably less expensive than Activase.
PROTOCOL FOR RT-PA THROMBOLYSIS
Alteplase (50 mg) is reconstituted in sterile water for injection (USP) to a concentration of 1 mg/mL. Alteplase contains no antibacterial pre servatives. The drug should be prepared immediately before use and diluents that contain bacteriocidal agents should not be used. However, normal saline may be used for dilution of the reconstituted agent. The manufacturer states that Activase should be used within 8 hours of preparation. However, in vitro experiments indicate that 1 mg/mL solutions are
PROTOCOL FOR RETEPLASE THROMBOLYSIS
Reteplase is reconstituted with sterile water to a concentration of 1 U/mL; the solution contains no bacteriocidal agents. The drug can be diluted with normal saline to 0.02 U/mL and remains active (and physically and biologically stable) for at least 24 hours. The freshly reconstituted drug (10 U in 10 mL sterile water) may be frozen to −20°C for as long as 2 weeks and then thawed without significant loss of activity (Centocor, data on file, 1999). Half-milliliter aliquots (0.5 U) may be
CONCLUSION
The removal of UK from the U.S. marketplace has forced interventional radiologists to rethink the management of patients with peripheral vascular occlusive disease. The initial “shotgun” approach to the use of rt-PA and reteplase in noncoronary thrombolysis has evolved into more rational strategies for treatment based on existing published work and growing experience with these agents. Prospective clinical trials will be required to establish the safest and most effective protocols for use of
References (77)
- et al.
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism
Am Heart J
(1999) - et al.
Femoro-popliteal artery thrombolysis with intra-arterial infusion of recombinant tissue-type plasminogen activator-report of a pilot trial
Eur J Vasc Surg
(1988) - et al.
Recombinant human tissuetype plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: preliminary report
J Vasc Surg
(1989) - et al.
Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease
JVIR
(1995) - et al.
Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissuetype plasminogen activator (rt-PA)
Eur J Endovasc Surg
(1996) - et al.
Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions
Eur J Radiol
(1996) - et al.
Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts
Am J Surg
(1996) - et al.
Thrombolysis of the occluded prosthetic graft with tissue-type plasminogen activator-technique, results, and problems in 23 patients
Clin Radiol
(1992) - et al.
Thrombolysis with tissue-plasminogen activator: results with a highdose transthrombus technique
J Vasc Surg
(1994) - et al.
Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction
Am J Med
(1988)
Thrombolysis in myocardial infarction (TIMI) trial—phase 1: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
J Am Coll Cardiol
Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding
JVIR
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis: results of a randomized trial
Chest
Randomized controlled trial of tissue plasminogen activator in proximal deep vein thrombosis
Am J Med
Catheter-directed thrombolysis of iliofemoral deep vein thrombosis: a new approach via the posterior tibial vein
Eur J Vasc Endovasc Surg
A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-directed thrombolysis
J Vasc Surg
Pulse-spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator
JVIR
The use of tissue plasminogen activator to declot arteriovenous access in hemodialysis patients
Am J Kidney Dis
Impairment of fibrinolysis by streptokinase, urokinase, and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents
J Am Coll Cardiol
Hemodialysis graft declotting: description of the “lyse and wait” technique
JVIR
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease
Am J Med Sci
Current thrombolytic agents: comparative analysis
Thrombolytic agents in development
Drugs
Evaluation of thrombolytic agents
Drugs
Urokinase
Alteplase: a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction
Drugs
Plasminogen activators: pharmacology and therapy
Radiology
A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators
N Engl J Med
Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase
JVIR
Thrombolytic therapy of peripheral arterial occlusions with recombinant staphylokinase
Circulation
Thrombolytic therapy
Adv Internal Med
Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers
Thromb Haemostasis
Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a doubleblind, randomized angiographic trial of lanoteplase versus alteplase
Circulation
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial
Am Heart J
Plasminogen activator (urokinase) from cultured cells
Thromb Haemost
Talk Paper, Food and Drug Administration, July 16, 1999
Thrombolytic therapy with recombinant human tissue-type plasminogen activator: a comparison of two doses
Radiology
Local thrombolytic therapy of acute peripheral arterial ischaemia with tissue plasminogen activator: a dose-ranging study
Br J Surg
Cited by (44)
Safety and Efficacy of Ultra-high-dose, Short-term Thrombolysis with rt-PA for Acute Lower Limb Ischemia
2013, European Journal of Vascular and Endovascular SurgeryCitation Excerpt :In some large trials which compared thrombolytic treatment with surgical revascularization, a decrease in mortality in patients randomized to lytic therapy was observed.2,3,5 Other randomized trials of thrombolysis have focused on the method of infusion, the kind of fibrinolytic agent and the dose.6–9 However, despite numerous publications, there is no consensus that one of the techniques is superior to the others, and the optimum dose, dosing regimen, and technique of administration of new thrombolytic agents have not been ultimately determined.4,10–12
Principles of Thrombolysis
2011, Endovascular SurgeryPrinciples of Thrombolysis
2010, Endovascular Surgery: Expert ConsultChasing Clot: Thrombophilic States and the Interventionalist
2009, Journal of Vascular and Interventional RadiologyContinuous improvement process for a high-risk population: Catheter-directed thrombolytic infusions
2009, Journal of Vascular NursingCitation Excerpt :Our rates of bleeding complications (23% with a mild site bleed or hematoma and 4.9% with a moderate bleed requiring a transfusion and no severe bleeds) are within the ranges cited in the literature. One of the issues identified in a review by Valji,9 is the broad range of complication rates reported in the literature. He cites a range of minor bleeding complications from 0%-63% and major bleeding complications from 0%-35%.
- 2
The author is a consultant for Genentech, Inc.